<p>The Long Non-Coding RNA SBF2-AS1 Exerts Oncogenic Functions In Gastric Cancer By Targeting The miR-302b-3p/E2F Transcription Factor 3 Axis</p>

Abstract

Background and aimsStudies show that the long non-coding RNA, SBF2-AS1, plays a critical role in cancer progression, but the role of SBF2-AS1 in gastric cancer has not been reported. Therefore, this study aimed to elucidate the mechanism of SBF2-AS1 in gastric cancer (GC).MethodsA meta-analysis, based on the gene expression omnibus database and TCGA dataset was performed to explore the prognostic value of SBF2-AS1 in GC. RT-PCR was also conducted to investigate the clinicopathologic value of SBF2-AS1 in GC. The effect of SBF2-AS1 in GC cell lines was conducted by gain or loss-of-function assays, and the SBF2-AS1 target gene was confirmed using a luciferase reporter assay and bioinformatics.ResultsSBF2-AS1 was overexpressed in GC tissues and cell lines, and SBF2-AS1 overexpression indicated poor overall survival and could serve as an independent prognostic factor. Moreover, knockdown of SBF2-AS1 inhibited cell growth, invasion, and metastasis, promoted apoptosis, and caused cell cycle arrest. Luciferase reporter and gain- or loss-of-function assays indicated that SBF2-AS1 acted as a competing endogenous (ceRNA) for microRNA (miR)-302b-3p, which blocked the inhibitory effect of miR-302b-3p on the E2F transcription factor 3 (E2F3).ConclusionSBF2-AS1 could be a potential diagnostic and prognostic biomarker in GC, and SBF2-AS1 accelerates tumor progression via the miR-302b-3p/E2F3 axis.

Long Noncoding RNASBF2-AS1 Promotes Gastric Cancer Progression via Regulating miR-545/EMS1 Axis

“…However, the expression level and biological role of SBF2-AS1 in GC remains largely unclear. In the present study, we examined the expression levels of SBF2-AS1 in GC tissues and cell lines and found that the expression of SBF2-AS1 was upregulated in GC tissues and cell lines compared with adjacent normal tissues and normal gastric epithelial cell line GES1, which BioMed Research International was consistent with previous result [15]. In particular, patients with advanced TNM stages or distant metastasis had a high expression of SBF2-AS1.…”

“…SBF2 antisense RNA 1 (SBF2-AS1), located at the 11p15.1 locus, has been shown to play critical roles in tumor progression and function as an oncogene in several types of cancers, such as nonsmall lung cancer, cervical cancer, glioblastoma, colorectal cancer, esophageal squamous cell carcinoma, and hepatocellular carcinoma [9][10][11][12][13][14]. Although a study showed that SBF2-AS1 expression was upregulated in GC tissues [15], the roles and underlying mechanisms of SBF2-AS1 in GC remain largely unknown and need investigation. To this end, the aims of this study were to examine the expression and functional role of SBF2-AS1 in the progression and development of GC and to identify the molecular mechanism of SBF2-AS1 involved in GC progression.…”

Circular RNA CDR1as promotes tumor progression by regulating miR-432-5p/E2F3 axis in pancreatic cancer

“…It is known that miRNAs bind to mRNAs to regulate tumorigenesis. According to previous studies, miR-432-5p could target and regulate E2F3, playing an important role in breast cancer [22], nasopharyngeal cancer [23], osteosarcoma [24], melanoma [25], and gastric cancer [26]. We also found that 1miR-432-5p sponged and negatively regulated E2F3 in PC cells.…”

The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis

“…Many studies have reported that lncRNAs combine competitively with miRNA binding sites to control gene expression [ 22 – 24 ]. Previous studies demonstrated that GAS5 may interact with miRNA to reduce protein expression [ 25 – 28 ].…”